Inhibition of eIF4F complex loading inhibits the survival of malignant glioma

Dong,Qiu‑Feng; Yan,Zhi‑Feng; Li,Peng‑Qi; Yang,Xin; Huo,Jun‑Li; Zhen,Hai‑Ning

doi:10.3892/or.2018.6587

Inhibition of eIF4F complex loading inhibits the survival of malignant glioma

Authors:
- Qiu‑Feng Dong
- Zhi‑Feng Yan
- Peng‑Qi Li
- Xin Yang
- Jun‑Li Huo
- Hai‑Ning Zhen
View Affiliations

Affiliations: Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/or.2018.6587
Pages: 2399-2407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The eukaryotic initiation factor (eIF)4E‑binding proteins (4E‑BPs) regulate cap‑dependent protein translation and control the assembly of the eIF4F complex. In the present study, a phosphorylation‑deficient truncated 4E‑BP2 (eIF4FD) was constructed into the eukaryotic expression vector pSecTag2, and the in vitro and in vivo effects on malignant glioma survival were determined through inhibiting eIF4F complex assembly. Cell cycle distribution analysis and TUNEL staining show that overexpression of eIF4FD suppressed cell proliferation and induced apoptosis in U251 cells. Western blotting showed that the cell cycle‑related genes cyclin D1 and C‑myc, and anti‑apoptotic genes B‑cell lymphoma 2 (Bcl‑2), Bcl‑extra large and survivin were reduced following the overexpression of eIF4FD. Furthermore, eIF4FD suppressed glioma vascularization via reductions in the expression of β‑catenin and vascular endothelial growth factor. In the orthotopic xenograft model, the stable expression of eIF4FD in U251 cells attenuated cell growth and increased the rate of apoptosis. Accordingly, pSecTag2‑PTD‑eIF4FD injection via the tail vein of mice also lead to cell growth inhibition and the induction of apoptosis. Therefore, the study showed that phosphorylation‑deficient truncated 4E‑BP2 efficiently inhibited eIF4E and prevented the formation of the eIF4F complex, which further contributed to the inhibition of cell proliferation and vascularization, and the induction of apoptosis. Therefore, the 4E‑BP2‑based phosphorylation‑deficient truncation designed in the present study may represent a novel approach for the targeted therapy of human malignant glioma though inhibition of the translation initiation complex.

View Figures

View References

1	Bastien JI, McNeill KA and Fine HA: Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer. 121:502–516. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T and Pollack IF: Dinaciclib, a Cyclin-Dependent Kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances ABT-737 mediated cell death in malignant human glioma cell lines. J Pharmacol Exp Ther. 356:354–365. 2016. View Article : Google Scholar : PubMed/NCBI
3	Rybalkina EY, Pavlova GV and Stavrovskaya AA: Recent news in the glioblastoma research. Biochem Moscow Suppl Ser A. 9:1–12. 2015. View Article : Google Scholar
4	Graff JR, Konicek BW, Carter JH and Marcusson EG: Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68:631–634. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hagner PR, Abraham S and Gartenhaus RB: Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 115:2127–2135. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hsieh AC and Ruggero D: Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 16:4914–4920. 2010. View Article : Google Scholar : PubMed/NCBI
7	Rhoads RE: eIF4E: New family members, new binding partners, new roles. J Biol Chem. 284:16711–16715. 2009. View Article : Google Scholar : PubMed/NCBI
8	Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 117:2638–2648. 2007. View Article : Google Scholar : PubMed/NCBI
9	Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ and Medeiros LJ: Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 169:2171–2180. 2006. View Article : Google Scholar : PubMed/NCBI
10	Karni R, Gus Y, Dor Y, Meyuhas O and Levitzki A: Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol. 25:5031–5039. 2005. View Article : Google Scholar : PubMed/NCBI
11	Torres VA, Tapia JC, Rodriguez DA, Lladser A, Arredondo C, Leyton L and Quest AF: E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription. Mol Cell Biol. 27:7703–7717. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lin CJ, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW and Pelletier J: Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep. 1:325–333. 2012. View Article : Google Scholar : PubMed/NCBI
13	Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, et al: eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 513:105–109. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhou H and Huang S: Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 12:30–42. 2011. View Article : Google Scholar : PubMed/NCBI
15	Robichaud N and Sonenberg N: eIF4E and Its Binding ProteinsParsyan A: Translat Regulat Cancer Biol Med. Springer; Dordrecht: pp. 73–113. 2014
16	Satheesha S, Cookson VJ, Coleman LJ, Ingram N, Madhok B, Hanby AM, Suleman CA, Sabine VS, Macaskill EJ, Bartlett JM, et al: Response to mTOR inhibition: Activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer. 10:192011. View Article : Google Scholar : PubMed/NCBI
17	Ayuso MI, Martinez-Alonso E, Salvador N, Bonova P, Regidor I and Alcázar A: Dissociation of eIF4E-binding protein 2 (4E-BP2) from eIF4E independent of Thr³⁷/Thr⁴⁶ phosphorylation in the ischemic stress response. PLoS One. 10:e01219582015. View Article : Google Scholar : PubMed/NCBI
18	Lukhele S, Bah A, Lin H, Sonenberg N and Forman-Kay JD: Interaction of the eukaryotic initiation factor 4E with 4E-BP2 at a dynamic bipartite interface. Structure. 21:2186–2196. 2013. View Article : Google Scholar : PubMed/NCBI
19	Patel LN, Zaro JL and Shen WC: Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res. 24:1977–1992. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wagstaff KM and Jans DA: Protein transduction: Cell penetrating peptides and their therapeutic applications. Curr Med Chem. 13:1371–1387. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ozawa T, Wang J, Hu LJ, Bollen AW, Lamborn KR and Deen DF: Growth of human glioblastomas as xenografts in the brains of athymic rats. In Vivo. 16:55–60. 2002.PubMed/NCBI
22	Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, et al: Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J Neurooncol. 85:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
23	Doherty JE, Woodard LE, Bear AS, Foster AE and Wilson MH: An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. FASEB J. 27:3753–3762. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wu M, Liu Y, Di X, Kang H, Zeng H, Zhao Y, Cai K, Pang T, Wang S, Yao Y and Hu X: EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma. Med Oncol. 30:4002013. View Article : Google Scholar : PubMed/NCBI
25	Pettersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM and Miller WH Jr: Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res. 75:1102–1112. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF and Xia LP: Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 28:1302–1307. 2011. View Article : Google Scholar : PubMed/NCBI
27	Campbell L, Jasani B, Griffiths DF and Gumbleton M: Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res. 5:2838–2848. 2015.PubMed/NCBI
28	Yang X, Dong QF, Li LW, Huo JL, Li PQ, Fei Z and Zhen HN: The cap-translation inhibitor 4EGI-1 induces mitochondrial dysfunction via regulation of mitochondrial dynamic proteins in human glioma U251 cells. Neurochem Int. 90:98–106. 2015. View Article : Google Scholar : PubMed/NCBI
29	Di Marino D, D'Annessa I, Tancredi H, Bagni C and Gallicchio E: A unique binding mode of the eukaryotic translation initiation factor 4E for guiding the design of novel peptide inhibitors. Protein Sci. 24:1370–1382. 2015. View Article : Google Scholar : PubMed/NCBI
30	Liao A, Shi R, Jiang Y, Tian S, Li P, Song F, Qu Y, Li J, Yun H and Yang X: SDF-1/CXCR4 axis regulates cell cycle progression and epithelial-mesenchymal transition via up-regulation of survivin in glioblastoma. Mol Neurobiol. 53:210–215. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kim KI, Cho HJ, Hahn JY, Kim TY, Park KW, Koo BK, Shin CS, Kim CH, Oh BH, Lee MM, et al: Beta-catenin overexpression augments angiogenesis and skeletal muscle regeneration through dual mechanism of vascular endothelial growth factor-mediated endothelial cell proliferation and progenitor cell mobilization. Arterioscler Thromb Vasc Biol. 26:91–98. 2006. View Article : Google Scholar : PubMed/NCBI
32	Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, Avdulov S, Mohorn RP, Whitson BA, Bitterman PB, et al: Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 66:4256–4262. 2006. View Article : Google Scholar : PubMed/NCBI
33	Yang H, Li LW, Shi M, Wang JH, Xiao F, Zhou B, Diao LQ, Long XL, Liu XL and Xu L: In vivo study of breast carcinoma radiosensitization by targeting eIF4E. Biochem Biophys Res Commun. 423:878–883. 2012. View Article : Google Scholar : PubMed/NCBI